DK0854874T3 - Makrocykliske lactonforbindelser og fremgangsmåde til fremstilling af disse - Google Patents

Makrocykliske lactonforbindelser og fremgangsmåde til fremstilling af disse

Info

Publication number: DK0854874T3
Authority: DK; Denmark
Prior art keywords: macrocyclic lactone; processes; preparation; lactone compounds; compound
Prior art date: 1994-11-10

Application number

DK95932876T

Other languages

English (en)

Inventor

Pharm Inc Nagoya Plan H-Pfizer

Phar Inc Nagoyaplant Y-Pfizer

Phar Inc Nagoya Plant T-Pfizer

Phar Inc Nagoya Plant Y-Pfizer

Pharm Inc Nagoya Plan N-Pfizer

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-10

Filing date

1995-10-13

Publication date

2003-06-02

1995-10-13 Application filed by Pfizer filed Critical Pfizer

2003-06-02 Application granted granted Critical

2003-06-02 Publication of DK0854874T3 publication Critical patent/DK0854874T3/da

Links

-1 lactone compounds Chemical class 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 3
150000001875 compounds Chemical class 0.000 abstract 2
XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 abstract 1
241000187712 Actinoplanes sp. Species 0.000 abstract 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 abstract 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
229930182821 L-proline Natural products 0.000 abstract 1
230000001857 anti-mycotic effect Effects 0.000 abstract 1
239000002543 antimycotic Substances 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
238000000855 fermentation Methods 0.000 abstract 1
230000004151 fermentation Effects 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229960002429 proline Drugs 0.000 abstract 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Transplantation (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pyrane Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Epoxy Compounds (AREA)
Saccharide Compounds (AREA)
Polyesters Or Polycarbonates (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK95932876T 1994-11-10 1995-10-13 Makrocykliske lactonforbindelser og fremgangsmåde til fremstilling af disse DK0854874T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP9401896		1994-11-10
PCT/IB1995/000870 WO1996015131A1 (en)	1994-11-10	1995-10-13	Macrocyclic lactone compounds and their production process

Publications (1)

Publication Number	Publication Date
DK0854874T3 true DK0854874T3 (da)	2003-06-02

Family

ID=1341416

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95932876T DK0854874T3 (da)	1994-11-10	1995-10-13	Makrocykliske lactonforbindelser og fremgangsmåde til fremstilling af disse

Country Status (12)

Country	Link
US (2)	US6001998A (da)
EP (1)	EP0854874B1 (da)
JP (1)	JP3061863B2 (da)
AT (1)	ATE239024T1 (da)
CA (1)	CA2204739C (da)
DE (1)	DE69530616T2 (da)
DK (1)	DK0854874T3 (da)
ES (1)	ES2194054T3 (da)
FI (1)	FI971995L (da)
MX (1)	MX9703484A (da)
PT (1)	PT854874E (da)
WO (1)	WO1996015131A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69530616T2 (de) *	1994-11-10	2004-04-01	Pfizer Inc.	Macrocyklische lactonverbindungen und verfahren zu ihrer herstellung
US20040235889A1 (en) *	2001-05-02	2004-11-25	Miao-Kun Sun	Carbonic anhydrase activator for enhancing learning and memory
US6551591B1 (en)	2001-09-07	2003-04-22	Essential Therapeutics, Inc.	Antibiotics from microbispora
US20080004332A1 (en) *	2002-03-07	2008-01-03	Alkon Daniel L	Methods for alzheimer's disease treatment and cognitive enhancement
US6825229B2 (en)	2002-03-07	2004-11-30	Blanchette Rockefeller Neurosciences Institute	Methods for Alzheimer's Disease treatment and cognitive enhancement
US20050065205A1 (en) *	2002-03-07	2005-03-24	Daniel Alkon	Methods for Alzheimer's disease treatment and cognitive enhance
MXPA06009440A (es) *	2004-02-17	2007-03-15	Thomas E Johnson	Metodos, composiciones y aparatos para la formacion de compuestos macrociclicos.
TW201206425A (en)	2004-05-18	2012-02-16	Brni Neurosciences Inst	Treatment of depressive disorders
WO2006115509A2 (en)	2004-06-24	2006-11-02	Novartis Vaccines And Diagnostics Inc.	Small molecule immunopotentiators and assays for their detection
CA2598805A1 (en) *	2005-02-24	2006-08-31	Biocern, Inc.	Sperm cell separation methods and compositions
WO2006119211A2 (en) *	2005-05-02	2006-11-09	Genaera Corporation	Methods and compositions for treating ocular disorders
US20070054890A1 (en) *	2005-07-29	2007-03-08	Alkon Daniel L	Protein synthesis required for long-term memory is induced by PKC activation on days preceding associative learning
CN103961347A (zh)	2006-07-28	2014-08-06	布朗歇特洛克菲勒神经科学研究所	刺激细胞生长、突触重塑和巩固长期记忆的方法
BRPI0714897A2 (pt) *	2006-08-30	2013-10-29	Biocern Inc	Sequência de ácido nucléico isolado e composição obtida, método de separação de uma mistura de células espermáticas, método de produção de uma sequencia de ácidos nucléicos e população de células espermáticas produzidas pelo método, kit de insenminação artificial de um mamífero contendo a população de células espermáticas e respactivo método de inseminação artificial
US8088789B2 (en)	2006-09-13	2012-01-03	Elixir Medical Corporation	Macrocyclic lactone compounds and methods for their use
EP2083834B1 (en) *	2006-09-13	2017-06-21	Elixir Medical Corporation	Macrocyclic lactone compounds and methods for their use
US10695327B2 (en)	2006-09-13	2020-06-30	Elixir Medical Corporation	Macrocyclic lactone compounds and methods for their use
WO2008100450A2 (en)	2007-02-09	2008-08-21	Blanchette Rockefeller Neurosciences Institute	Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury
EP3332797A3 (en)	2007-02-09	2018-08-01	Blanchette Rockefeller Neurosciences Institute	Therapeutic effects of bryostatins, bryologs and other related substances on head trauma-induced memory impairment and brain injury
WO2010126888A1 (en) *	2009-05-01	2010-11-04	Glycomimetics, Inc.	Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
ES2637447T3 (es) *	2009-08-31	2017-10-13	Dr. Reddy's Laboratories Ltd.	Formulaciones tópicas que contienen un esteroide
US9107890B2 (en)	2010-07-08	2015-08-18	Blanchette Rockefeller Neurosciences Institute	PKC activators and anticoagulant in regimen for treating stroke
CA2808660A1 (en)	2010-08-19	2012-02-23	Blanchette Rockefeller Neurosciences Institute	Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators
JP6422778B2 (ja)	2011-11-13	2018-11-14	ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート	Ｐｋｃアクチベーターおよびその組合せ
WO2016183252A1 (en)	2015-05-11	2016-11-17	Alkon, Daniel, L.	Treatment of neurodegenerative conditions using pkc activators after determining the presence of the apoe4 allele
CN107827803A (zh) *	2017-11-28	2018-03-23	绍兴厚普生物科技有限责任公司	一种从发酵液中提取l‑羟脯氨酸的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1910715A1 (de) *	1968-03-04	1969-10-09	Stanley Drug Products Inc	Antimikrobielle Faktoren und deren Verwendung
US5091389A (en) *	1991-04-23	1992-02-25	Merck & Co., Inc.	Lipophilic macrolide useful as an immunosuppressant
US5674732A (en) *	1992-04-27	1997-10-07	Pfizer Inc.	Rapamycin producer
CA2106034A1 (en) *	1992-09-24	1994-03-25	Ralph J. Russo	21-norrapamycin
DE69530616T2 (de) *	1994-11-10	2004-04-01	Pfizer Inc.	Macrocyklische lactonverbindungen und verfahren zu ihrer herstellung

1995
- 1995-10-13 DE DE69530616T patent/DE69530616T2/de not_active Expired - Fee Related
- 1995-10-13 CA CA002204739A patent/CA2204739C/en not_active Expired - Fee Related
- 1995-10-13 ES ES95932876T patent/ES2194054T3/es not_active Expired - Lifetime
- 1995-10-13 DK DK95932876T patent/DK0854874T3/da active
- 1995-10-13 US US08/836,213 patent/US6001998A/en not_active Expired - Fee Related
- 1995-10-13 FI FI971995A patent/FI971995L/fi not_active IP Right Cessation
- 1995-10-13 WO PCT/IB1995/000870 patent/WO1996015131A1/en not_active Ceased
- 1995-10-13 EP EP95932876A patent/EP0854874B1/en not_active Expired - Lifetime
- 1995-10-13 MX MX9703484A patent/MX9703484A/es not_active IP Right Cessation
- 1995-10-13 PT PT95932876T patent/PT854874E/pt unknown
- 1995-10-13 JP JP8515869A patent/JP3061863B2/ja not_active Expired - Lifetime
- 1995-10-13 AT AT95932876T patent/ATE239024T1/de not_active IP Right Cessation
1999
- 1999-08-20 US US09/378,062 patent/US6187568B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
FI971995A0 (fi)	1997-05-09
JPH11507907A (ja)	1999-07-13
MX9703484A (es)	1997-08-30
DE69530616T2 (de)	2004-04-01
JP3061863B2 (ja)	2000-07-10
CA2204739C (en)	2000-04-04
PT854874E (pt)	2003-07-31
FI971995A7 (fi)	1997-05-09
EP0854874B1 (en)	2003-05-02
US6001998A (en)	1999-12-14
US6187568B1 (en)	2001-02-13
EP0854874A1 (en)	1998-07-29
ATE239024T1 (de)	2003-05-15
WO1996015131A1 (en)	1996-05-23
FI971995L (fi)	1997-05-09
DE69530616D1 (de)	2003-06-05
ES2194054T3 (es)	2003-11-16

Publication	Publication Date	Title
DK0854874T3 (da)	2003-06-02	Makrocykliske lactonforbindelser og fremgangsmåde til fremstilling af disse
MY140677A (en)	2010-01-15	Modified amino acids, pharmaceuticals containing these compounds and method for their production
MXPA02004415A (es)	2004-09-10	Pirazolonas sustituidas con heterociclicas.
RU94042903A (ru)	1996-10-27	3,4,4-трехзамещенные пиперидинил-n-алкилкарбоксилаты и промежуточные соединения, способ их получения, фармкомпозиция
GR3030342T3 (en)	1999-09-30	Cyclobutane derivatives as inhibitors of squalene synthetase and protein farnesyltransferase.
BG100951A (en)	1997-08-29	Novel erythromycin derivatives, method for their preparation and their use as drugs
MX9707706A (es)	1997-12-31	Compuestos intermediarios novedosos y proceso para la manufactura de derivados de la camptotecina (cpt-11) y compuestos relacionados.
WO2002060879A3 (en)	2003-03-27	Bacterial gyrase inhibitors and uses thereof
ZA979553B (en)	1998-05-21	Bacterial strains and use thereof in fermentation processes for 2-keto-L-gulonic acid production.
DE69732413D1 (de)	2005-03-10	Verfahren zur synthese chemischer verbindungen mit pde-iv-hemmender wirkung
MY145819A (en)	2012-04-30	Process and intermediates useful in the preparation of pharmaceutical compounds as fulvestrant
EA200100347A1 (ru)	2001-10-22	Метод и композиция для лечения и профилактики туберкулеза
NO974320L (no)	1997-10-27	Fucopeptider
AU1306795A (en)	1995-07-10	Anticonvulsant pseudofructopyranose sulfamates
ATE475653T1 (de)	2010-08-15	Verfahren zur herstellung von valsartan
SI1102765T1 (en)	2003-12-31	PROCESS FOR THE SYNTHESIS OF (1$i(H))-BENZO C)QUINOLIZIN-3-ONES DERIVATIVES
GR3033402T3 (en)	2000-09-29	Selective process for the deacylation of acylated compounds
DK0852232T3 (da)	2002-04-22	Cykliske peptidforbindelser til behandling af smerte og deres fremstillingsproces
AU3259997A (en)	1998-01-07	Ring-fused dihydropyranes, process for the preparation and use thereof
ATE375343T1 (de)	2007-10-15	Neue beta-lactamverbindungen und verfahren zu deren herstellung
BG103704A (en)	2000-05-31	New compounds
TW376386B (en)	1999-12-11	Bioregulatory active substance, method for its production and use thereof
DK0638125T3 (da)	1996-05-13	Actinoplaner til produktion af rapamycin
CA2230303A1 (en)	1997-03-06	Polymorphs of the prodrug 6-n-(l-ala-l-ala)-trovafloxacin
KR960037685A (ko)	1996-11-19	암모니오세팔로스포린 계열 항생제 및 그의 제조방법